56 results about "African Green Monkey" patented technology

The invention relates to the field of vaccine preparation, and particularly relates to a cell strain for producing a goatpox vaccine. The cell strain is an African green monkey kidney cell Vero B10 and is collected at China General Microbiological Culture Collection Center with the collection number of CGMCC No. 9705. Compared with a primary cell production method, a preparation method of the cell strain has the advantages that a goatpox virus strain AV41 is cultivated by using a VeroB10 cell, good in virus adaptability and low in strong recurrence risk; a passage cell vaccine is superior to a primary cell vaccine in terms of virus yield, uniformity, pureness and the like; the cost is low, and animals are not needed; and the safety of the passage cell vaccine is superior to that of the primary cell vaccine, and the immunity efficiency of the passage cell vaccine is not lower than that of the primary cell vaccine.

A duck hemorrhagic oophoritis inactivated vaccine production method by using a cell line and a product thereof belong to the field of biotechnology. According to the method provided by the invention, the cell line is selected from hamster kidney cell line or African green monkey kidney cell line, and the preparation of the vaccine is accomplished by the following steps of: (1) breeding strain, (2) establishing virus seed group, (3) preparing cell venom, (4) inactivating virus, (5) washing and concentrating cell venom, (6) emulsifying and the like. The method provided by the invention has characteristics of simple and stable production process, easy operation and high security. The prepared duck hemorrhagic oophoritis inactivated vaccine has advantages of high quality, high yield, low cost, small inter-batch difference, good safety and high immune efficacy.

A multiplex polymerase chain reaction assay that targets nine tetranucleotide short tandem repeat (STR) markers in the mouse genome. Unique profiles were obtained from seventy-two mouse samples that were used to determine the allele distribution for each STR marker. Correlations between allele fragment length and repeat number were determined with DNA Sanger sequencing. Genotypes for L929 and NIH3T3 cell lines were shown to be stable with increasing passage numbers as there were no significant differences in fragment length with samples of low passage when compared to high passage samples. In order to detect cell line contaminants, primers for two human STR markers were incorporated into the multiplex assay to facilitate detection of human and African green monkey DNA. This multiplex assay is the first of its kind to provide a unique STR profile for each individual mouse sample and can be used to authenticate mouse cell lines.

The invention belongs to the technical field of medicines, and relates to a novel application of vitamin B12 in pharmacy, in particular to an application of vitamin B12 in preparation of a medicine for resisting novel coronavirus. Experiments prove that the vitamin B12 can inhibit infection of the novel coronavirus on in-vitro cell culture Vero-E6 (African green monkey kidney cells), new application of the vitamin B12 in treatment of the novel coronavirus caused by the novel coronavirus is developed, and a new medicine is provided for treatment and control of the novel coronavirus.

The invention described herein provides a method for selecting a novel African Green monkey kidney (AGMK) cell substrate, its cultivation and serial passage and its subsequent characterization. The invention provides a method for the use of the cell substrate in the isolation, growth and serial passage of a large number of viruses, particularly rotaviruses, enteroviruses, respiratory viruses and hepatitis A virus. The invention provides a method for the utilization of this AGMK cell substrate for the production of live and killed virus vaccines.

The invention discloses a constitutive promoter-like gene VP2 which is found from a eukaryotic cell African green monkey kidney cell (Vero) and can be used for promoting heterologous protein expression in a prokaryotic cell, and a truncating sequence Vh2 of the constitutive promoter-like gene VP2. A nucleotide sequence of the promoter-like gene VP2 is shown as SEQ ID NO: 1; the nucleotide sequence of the truncating sequence is shown as 60bp to 107bp in SEQ ID NO: 1; the gene is constructed to form an expression reporter gene chloramphenicol acetyl transferase (CAT) gene recombinant vector for screening; the screened vector and a gene segment to be screened are recombined, and a gene library is constructed; a promoter-like sequence is obtained by a recombinant strain containing a promoter-like gene sequence through a method for screening the resistance of chloramphenicol; the sequence can be used for efficiently starting and expressing heterologous protein in the prokaryotic cell.

The invention provides application of proanthocyanidin compounds shown by the formula (I) as shown in the specification or a pharmaceutically acceptable salt thereof to preparation of a drug against Zika virus, and provides the novel application of the proanthocyanidin compounds shown by the formula (I) in the specification or the pharmaceutically acceptable salt thereof in the pharmaceutical field. The compounds can effectively inhibit the expansion of Zika virus, and can be used as a lead compound to develop the drug for preventing and treating Zika virus infection. Active compounds have nosignificant cytotoxicity at the inhibitor dose and have a common parent nucleus structure, but the parent nucleus structure has no antiviral activity, wherein, the active compounds, namely proanthocyanidins, are found to have anti-Zika virus activity in African green monkey kidney cells and human glioma cells. The compounds have important application prospects.

The invention discloses an optimized technical method for proliferation of Coxsackie virus A16. The method includes: taking flaky fibers as carriers, proliferating African green monkey kidney cells in a bioreactor, adopting an 8v / v% serum containing DMEM (Dulbecco modified eagle medium) culture medium in a cell culture phase, changing into a serum-free DMEM culture medium in 5-6 days of cell culture, adopting a 3-5% serum containing DMEM culture medium after virus inoculation and adsorption, adopting a 0.5w / v% lactoalbumin hydrolysate added serum-free culture medium in a virus harvesting phase, statically re-adsorbing for 3h, continuing to culture, and replenishing 2.0g / L glucose about every 24h. The method is high in repeatability and stability, high virus titer can be achieved, and subsequent purification difficulty can be lowered while requirements of biological products are met. In addition, the method is high in application value and applicable to bioreactor based Coxsackie virus A16 proliferation with flaky fiber carriers.

The invention relates to the field of biotechnology, and in particular relates to an optimized process method for amplifying the enterovirus type 71. The method adopts a poly-fiber paper scrap as a carrier and amplifies an African green monkey kidney cell by use of a bioreactor so as to establish a whole process flow for copying and amplifying the enterovirus type 71. Under a condition of completely adapting to an enterovirus type 71 copying and amplifying system, the method adopts a DMEM (dulbecco's minimum essential medium) containing 10% of serum in a cell culture stage; after virus inoculation and adsorption for 24 hours, the method adopts a DMEM containing 3-5% of serum; 0.5% of lactoalbumin hydrolysate is added by use of a serum-free medium in a virus harvesting stage, and 2g / L of glucose is supplemented every 24 hours; and on the basis of reducing the later-period purifying difficulty and adapting to the requirements for a biological product, the optimized process realizes a higher virus titer. The method provided by the invention has good repeatability and efficient enterovirus type 71 amplifying process, and can be used for amplifying the enterovirus type 71 by use of a bioreactor by taking a poly-fiber paper scrap as a carrier.

The invention relates to a porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine and a preparation method of the porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine. The porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine is prepared by performing virus amplification on a swine testicular cell line (ST cells) or an African green monkey kidney cell line (Vero cells) by using a self-attenuated and preserved transmissible gastroenteritis virus SD / L strain and a self-attenuated and preserved porcine epidemic diarrhea virus LW / L strain, and carrying out the steps of harvesting, uniformly mixing, freeze-drying and the like. The porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine can effectively prevent two diseases namely swine transmissible gastroenteritis and epidemic diarrhea.

The invention discloses a semi-pouring flow type culture method for the duck Tembusu virus. The culture method comprises the steps that firstly, a cell culture device is used for carrying out virus reproduction, wherein the cell culture device containing a carrier is subjected to autoclaved sterilization, a culture solution is added, and African green monkey kidney cells are inoculated in a sterile mode; secondly, the culture solution is replaced, wherein the glucose content in the culture solution and the pH value are measured every day, and the culture solution is replaced; thirdly, virus inoculation is carried out, wherein allantoic fluid containing the duck Tembusu virus is inoculated, and virus multiplication culture is carried out; fourthly, the culture solution is supplemented, wherein crude virus liquor is collected, and then the fresh culture solution with the equal amount is supplemented to continue culture; fifthly, preservation is carried out, wherein the crude virus liquor collected in the fourth step is subjected to multigelation 1-5 times at minus 100-minus 20 DEG C, cell fragments are extracted through centrifuging after multigelation, filtering is carried out, and virus liquor is obtained and preserved at minus 20 DEG C. By means of the semi-pouring flow type culture method, the production efficiency of the virus can be improved, and crude virus liquor can be continuously gained multiple times every time each batch of cells are cultured.

Iron-doped apatite nanoparticles (IDANPs) are useful for the prevention, treatment, or alleviation of signs or symptoms associated with viral activation or infection. IDANPs have demonstrated a significant influence over herpes simplex virus 1 (HSV-1) infection of two mammalian cell lines. Specifically, IDANPs decreased HSV-1 infection of African Green Monkey kidney epithelial (Vero) cells by 84% and HSV-1 infection of human lung bronchus (BEAS-2B) cells by 71%. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Lactate Dehydrogenase (LDH) and XTT (2,3-Bis 2-methoxy-4-nitro-5-sulfophenyl-2H-tetrazolium-5-carboxanilide inner salt) cytotoxicity assays revealed that IDANPs are largely non-toxic to Vero, BEAS-2B, and human cervical cancer (HeLa) cells lines. HSV-1 afflicted individuals in the United States have been estimated as high as ⅔ the population. Because IDANPs dramatically decrease HSV-1 infection and are largely non-toxic, their application as an antiviral agent is evident. Further, although iron(III) alone has been shown to diminish replication of deoxyribonucleic acid (DNA)- and ribonucleic acid (RNA)-containing viruses, IDANP cytotoxicity studies indicate that encasement and delivery of iron within an apatite unit cell structure diminishes significantly, and in some cases eliminates, cytotoxicity posed by the introduction of iron(III) alone.

The invention provides a homologous recombination vector expressing eGFP, which belongs to the field of genome editing technology. The homologous recombination vector expressing eGFP includes a vector backbone and an insert segment, and the insert segment includes a left homology arm, a CMV promoter, An eGFP expression frame and a right homology arm; the nucleotide sequence of the left homology arm is shown in SEQ ID No.1; the nucleotide sequence of the right homology arm is shown in SEQ ID No.2. After the homologous recombination vector described in the present invention and the CRISPR / Cas9 targeting vector are co-transfected into vero cells, the vero cells are screened by G418 to obtain vero cells that integrate eGFP at a specific point and stably express eGFP. The cell construction method described in the present invention supports site-specific integration and stable expression of foreign genes.

The invention provides a coxsackie virus A16-type virus strain. The collection number of the coxsackie virus A16-type virus strain is CGMCC No.5372, wherein CGMCC refers to China General Microbiological Culture Collection Center. The virus is a 20-face stereoscopic symmetrical sphere under observation through an electron microscope, and the diameter of the virus is 23-30nm. VP1 conserved region sequence analysis and mass spectrum analysis are respectively performed on the virus strain, and a result shows a CA16 virus. The CA16 virus can be efficiently proliferated in Vero cells (African green monkey kidney cells), and the virus titer can reach 6.61g CCID50 / ml. Moreover, the virus strain has no external pollution, better immunogenicity and a good effect.